MF59: Clinical Trials

7 trials of MF59, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7

Follow MF59: new trials by email Literature Review of MF59 trials Research Report on MF59

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3722018-11-022021-05-17
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7 - Influenza, Human
Phase 2CompletedBiomedical Advanced Research and Development Authority3662017-09-202020-05-06
Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant
7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk) - A/Vietnam/H5N1 Influenza Virus
Phase 2CompletedBiomedical Advanced Research and Development Authority4222016-03-012020-08-31
H7N9 Mix and Match With MF59 in Healthy Elderly Persons
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)4792014-10-012017-07-06
H7N9 Mix and Match With MF59 in Healthy Adults
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 - Influenza
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)7002013-09-012016-12-12
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
AS03, MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Influenza
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)9802013-09-012017-07-06
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
CAD106, Placebo, Alum - Alzheimer's Disease
Phase 2CompletedNovartis Pharmaceuticals1772010-03-012021-03-05

Conditions studied

Influenza, Human (5)  ·  Influenza in Birds (3)  ·  Alzheimer Disease (1)  ·  Central Nervous System Diseases (1)  ·  Neurodegenerative Diseases (1)  ·  Orthomyxoviridae Infections (1)  ·  RNA Virus Infections (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Infections (1)  ·  Virus Diseases (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (4)  ·  Biomedical Advanced Research and Development Authority (2)  ·  Novartis Pharmaceuticals (1)

Countries

United States (7)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Spain (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Carlos Fierro, MD (1)  ·  Mark Adams, MD (1)  ·  Matthew Davis, MD (1)  ·  Terry Poling, MD (1)

Results publications

PMID 25291577, PMID 26197184, PMID 36273986, PMID 39798434

NIH funding

2009 (1)